Company

Apollomics

As of the edition of 20 October 2026, Apollomics runs 4 drugs; it is on route A at 2 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

The records place 2 company names in this family.

Drugs by status

StatusCount
Active2
Stopped2
Total4

Where it needs a new molecule

Route A at 2 targets, route B at 0 targets.

Three of its 2 rows, by target and route
TargetRoute
SELE E-selectinRoute A
PDCD1 Programmed cell death protein 1Route A

All 2 rows on route A or B

In the product

2 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Cancer: 5 trials led
  • Blood and lymph: 2 trials led
  • Digestive system: 2 trials led